PharmAust CEO Resignation and Interim Appointment

PharmAust Limited (ASX: $PAA), a clinical-stage biotechnology company, has announced the resignation of Chief Executive Officer Dr Michael Thurn for personal reasons. Dr Thurn has tendered his resignation, providing the Company with four months' notice as required under his contract. In response to this, John Clark, PharmAust's experienced Chief Operating Officer, has been appointed as the interim CEO. The transition of the CEO role will be facilitated by Dr Thurn and the Board over the next four months.

PharmAust Chairman's Statement on CEO Resignation and Interim Appointment

Chairman Dr Roger Aston expressed gratitude for Dr Michael Thurn's contributions and wished him well in his future endeavors. He also conveyed the Board's delight in appointing John Clark as the interim CEO, emphasizing the exciting phase PharmAust is entering and the aggressive pursuit of the company's clinical and commercial objectives, particularly the development and intended commercialization of monepantel for MND/ALS treatment.

PharmAust CEO Resignation and Interim Appointment Summary

PharmAust Limited (ASX: $PAA) has announced the resignation of CEO Dr Michael Thurn and the appointment of John Clark as the interim CEO. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases, particularly for the treatment of MND/ALS. PharmAust anticipates commencing enrollment in its pivotal registration adaptive Phase 2/3 clinical study in H2 CY 2024, aiming for accelerated approval with the US Food and Drug Administration in 2026. The announcement reflects the company's commitment to advancing its clinical and commercial objectives, aligning with the growing market for neurodegenerative disease treatments.